Each 100-unit increase in the Systemic Immune-Inflammation Index was independently associated with a 32.1% higher risk of cardiovascular mortality (OR 1.321) in patients with HFpEF.
Cohort (n=316)
No
Does the systemic immune-inflammation index (SII) improve prediction of cardiovascular outcomes compared to conventional inflammatory markers in patients with HFpEF?
The systemic immune-inflammation index (SII) may serve as a superior prognostic marker for adverse cardiovascular outcomes in HFpEF compared to traditional inflammatory markers like CRP, NLR, and SIRI.
Effect estimate: OR 1.321 (95% CI 1.191-1.467)
p-value: p=<0.001
Background: The systemic immune-inflammation index (SII), a novel inflammatory index integrating neutrophil, platelet, and lymphocyte counts, predicts outcomes in several cardiovascular diseases, yet its role in heart failure with preserved ejection fraction (HFpEF) remains unclear. We therefore investigated the prognostic value of SII in HFpEF patients and compares its performance against other inflammatory markers, including systemic inflammation response index (SIRI), neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP). Methods: We retrospectively analyzed a cohort of 316 patients with HFpEF diagnosed between January 2017 and January 2021. All-cause mortality, cardiovascular mortality and HF rehospitalization were assessed over a median follow-up of 24 months. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were employed to evaluate the comparative prognostic performance of SII against SIRI, NLR and CRP. Results: >0.05). Conclusion: SII emerges as a superior predictor of adverse cardiovascular outcomes in HFpEF compared to conventional inflammatory markers, supporting its use for risk stratification and as a potential therapeutic guide. Nevertheless, its association with all-cause mortality remains limited.
Zhu et al. (Thu,) conducted a cohort in Heart Failure with Preserved Ejection Fraction (HFpEF) (n=316). Systemic Immune-Inflammation Index (SII) vs. Conventional inflammatory markers (SIRI, NLR, CRP) was evaluated on Cardiovascular mortality (OR 1.321, 95% CI 1.191-1.467, p=<0.001). Each 100-unit increase in the Systemic Immune-Inflammation Index was independently associated with a 32.1% higher risk of cardiovascular mortality (OR 1.321) in patients with HFpEF.